Volume : 13, Issue : 10, October – 2026

Title:

PREFILLED SYRINGES: ADVANCEMENTS IN DRUG –DEVICE COMBINATION SYSTEMS

Authors :

Shubhangi. S. Hambharde, Khan Hajera *, Metku shriveni, Sarthak Gawande, Joshi Sheetal, Kubde Kanchan, Manoj Honsangde, Lolge Shruti, Kakde Vikas, Gharke Karan

Abstract :

Prefilled syringes (PFS) have undergone a paradigm shift, transitioning from passive primary container closure systems into complex, integrated drug-device combination products designed for modern biopharmaceuticals. Their ready-to-administer presentation streamlines clinical workflows, ensures rigorous dosing precision, minimizes contamination risks, and facilitates patient-centric home self-administration. The rapid proliferation of therapeutic monoclonal antibodies, recombinant proteins, peptides, and high concentration subcutaneous formulations has underscored the vital importance of container contact materials, silicone lubrication dynamics, needle geometry, and mechanical device integration. Contemporary PFS platforms encompass traditional Type I borosilicate glass, cyclic olefin polymer (COP), cyclic olefin copolymer (COC), and specialized silicone-reduced or silicone-free platforms. Each material matrix presents a distinct trade-off regarding gas/moisture barrier properties, fracture resistance, dimensional tolerances, extractables (E&L) profiles, and interface-induced drug degradation. For biological macromolecules, drug-container compatibility represents a critical quality attribute (CQA); protein adsorption and interfacial denaturation at glass, polymer, elastomer, air-liquid, and silicone-oil interfaces frequently induce subvisible particle generation and irreversible aggregation. Silicone oil microdroplets remain a focal technical challenge due to potential migration and nucleation effects, while residual manufacturing contaminants such as tungsten species can induce localized protein unfolding. Concurrently, injectability functionality is paramount for viscous high-concentration biologics, were hydraulic resistance and extrusion dynamics scale critically with needle lumen diameter and fluid rheology. This review provides a comprehensive review covering component architecture, material interaction pathways, silicone dynamics, fluid mechanical modelling, clinical human factors, regulatory frameworks, and next-generation smart delivery devices
Keywords: Prefilled syringe; Drug-device combination system; Primary container closure; Biologics stability; Monoclonal antibodies; Silicone oil migration; Cyclic olefin polymer (COP); Injectability mechanics; Autoinjectors; Extractables and Leachables (E&L)

Cite This Article:

Please cite this article in press Hajera Khan et al., Prefilled Syringes: Advancements In Drug–Device Combination Systems.,. Indo Am. J. P. Sci, 2026; 13(10).

REFERENCES:

1. FDA. Container Closure Systems for Packaging Human Drugs and Biologics: Chemistry, Manufacturing, and Controls Documentation. 1999.
2. FDA. Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products. 2013.
3. Seidl A, Hainzl O, Fichtl J, et al. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29(6):1454-1467.
4. Allmendinger A, Fischer S, Huwyler J, et al. Calculation of injection forces for highly concentrated protein solutions. Int J Pharm. 2015;493(1-2):70-74. doi: 10.1016/j.ijpharm.2015.07.012
5. Journal of Animal and Plant Research (2025). “Prefilled Syringes: A Comprehensive Review of Design, Manufacturing, Clinical Benefits, and Future Trends”.
6. Rathore AS, Sobacke R. Development of Biotechnology Products in Pre-filled Syringes: Technical Considerations and Approaches. BioProcess Int. 2011;9(6):34-44.
7. Shire SJ, Shahrokh Z, Liu J. (2004). Challenges in the development of high concentration formulations of therapeutic monoclonal antibodies. AAPS PharmSciTech, 5(3), 1-9. DOI: 10.1208/pt050348.
8. Jiang Y, et al. (2013). Tungsten-induced protein aggregation: mechanistic studies. Journal of Pharmaceutical Sciences, 102(4), 1137–1145. DOI: 10.1002/jps.23461.
9. Fang L, Rase M. (2024). Excipient and Packaging Material Impact on Glass and Polymer-Based Prefilled Syringe Functionality. PDA Journal of Pharmaceutical Science and Technology, 78(1), 70–89. DOI: 10.5731/pdajpst.2022.012760.
10. Krayukhina E, et al. (2015). Functional evaluation and characterization of a newly developed silicone oil-free prefillable syringe system. Journal of Pharmaceutical Sciences, 103(5), 1520–1528.
11. Badkar A, Wolf A, Bohack L, Kolhe P. Development of biotechnology products in pre-filled syringes: technical considerations and approaches. AAPS PharmSciTech. 2011; 12:564–572. DOI: 10.1208/s12249-011-9617-y.
12. Bee JS, et al. (2009). Precipitation of a monoclonal antibody by soluble tungsten. Journal of Pharmaceutical Sciences, 98(9), 3290–3299. DOI: 10.1002/jps.21657.
13. Wang X, Baron J, So J, et al. (2026). Pinch Force Endurance and Usability Considerations for Pre-Filled Syringe Designs Used by Chronic Obstructive Pulmonary Disease Patients. PDA Journal of Pharmaceutical Science and Technology, 80(3), 312–327. DOI: 10.5731/pdajpst.2025-000049.1.
14. Ma J. High-concentration biologic formulations: challenges, strategies, and emerging technologies for subcutaneous delivery. European Journal of Pharmaceutics and Biopharmaceutics. 2026; 226:115178. DOI: 10.1016/j.ejpb.2026.115178
15. Lou H, Feng M, Hageman MJ. (2022). Advanced Formulations/Drug Delivery Systems for Subcutaneous Delivery of Protein-Based Biotherapeutics. Journal of Pharmaceutical Sciences. 111(11):2968–2982. DOI: 10.1016/j.xphs.2022.08.036.
16. Circular Economy for Medical Devices: A Case Study of Syringes. (2024). Procedia CIRP, 122, 449–454. DOI: 10.1016/j.procir.2024.01.065.
17. Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies. Patient Preference and Adherence. 2018. Full text: PMC6147689.
18. Wang T, Richard CA, Clark SL. Development of an inductively coupled plasma mass spectrometry method for quantification of extracted tungsten from glass prefilled syringes used as a primary packaging for pharmaceutical and therapeutic protein products. PDA J Pharm Sci Technol. 2013;67(5):490-499. doi:10.5731/pdajpst.2013.00938
19. Markovic I. Identification of extractables by liquid chromatography-high resolution mass spectrometry: A case study to understand the extraction profile of different disposable syringes. J Pharm Biomed Anal. 2020; 190:113602. doi: 10.1016/j.jpba.2020.113602
20. Jenke D. Extractables and leachables considerations for prefilled syringes. Expert Opin Drug Deliv. 2014;11(10):1591-1600. doi:10.1517/17425247.2014.932766
21. Shire SJ. Cross-linked silicone coating: a novel prefilled syringe technology that reduces subvisible particles and maintains compatibility with biologics. Journal of Pharmaceutical Sciences. 2014. doi:10.1002/jps.23947. (PubMed PMID: 24643773).
22. Collins BE, Carpenter JF, Randolph TW. Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities. J Pharm Sci. 2018;107(1):10-22. doi: 10.1016/j.xphs.2017.09.008
23. United States Pharmacopeia. General Chapter <1664>: Assessment of Drug Product Leachable Associated with Pharmaceutical Packaging/Delivery Systems. USP–NF.
24. DePaz IM, et al. (2014). Effects of silicone oil on protein stability and protein-silicone oil interactions. Journal of Pharmaceutical Sciences, 103(12), 3846–3859. DOI: 10.1002/jps.24185.
25. Basu S, et al. (2014). Protein aggregation and particle formation in prefilled glass syringes. Journal of Pharmaceutical Sciences, 103(5), 1361–1369. DOI: 10.1002/jps.23973.
26. Ronk M, Liu J, Gallegos A, et al. (2020). Holistic Extractables and Leachable Program: Evaluations of Prefilled Syringe Systems for Biotechnology Products. PDA Journal of Pharmaceutical Science and Technology, 74(6), 627–643. DOI: 10.5731/pdajpst.2019.011379.
27. Werner BP, Schöne ich C, Winter G. (2019). Silicone Oil-Free Polymer Syringes for the Storage of Therapeutic Proteins. Journal of Pharmaceutical Sciences. 108(3):1148–1160. DOI: 10.1016/j.xphs.2018.10.049.
28. Makwana S, et al. (2011). Prefilled syringes: An innovation in parenteral technologies. International Journal of Pharmaceutical Investigation, 1(4), 200–206. DOI: 10.4103/2230-973X.93006.
29. Impact of Sterilization Method on Protein Aggregation and Particle Formation in Polymer-Based Syringes. (2017). Journal of Pharmaceutical Sciences. 106(4):1001–1007. DOI: 10.1016/j.xphs.2016.12.007.
30. Fujimori K, et al. (2022). Quantitative Evaluation of Insoluble Particulate Matters in Therapeutic Protein Injections Using Light Obscuration and Flow Imaging Methods. Journal of Pharmaceutical Sciences. 111(3):648–654. DOI: 10.1016/j.xphs.2021.09.047
31. Yoshino K, et al. (2021). Functional evaluation and characterization of cyclic olefin polymer syringes for storage of biopharmaceuticals. PDA Journal of Pharmaceutical Science and Technology, 75(2), 145–160. DOI: 10.5731/pdajpst.2020.011858.
32. Zheng Z, Renawala HK, Wuelfing WP, et al. (2026). Protein stability and viscosity in molecularly crowded high-concentration biologics. Advanced Drug Delivery Reviews. 233:115854. DOI: 10.1016/j.addr.2026.115854.
33. Improving prefilled syringe injectability: influences of critical component attributes and human factors. 2025/2026 publication. (PMID: 41093078).
34. Mechanistic and predictive formulation development for viscosity mitigation of high-concentration biotherapeutics. 2025/2026 review literature. (PMID: 40948459).
35. Garidel P, et al. High-concentration protein formulations: How high is high? European Journal of Pharmaceutics and Biopharmaceutics. 2017; 119:353–360. DOI: 10.1016/j.ejpb.2017.06.028.
36. Sreedhara A, et al. (2024). Human factors and usability engineering in the development of drug-device combination products: Prefilled syringes and autoinjectors. Medical Devices: Evidence and Research, 17, 45–58. DOI: 10.2147/MDER.S441209.
37. On-body drug delivery systems: State-of-the-art technologies, clinical application, and future perspectives. Drug Discovery Today (2025/2026).
38. The Adherence and Outcomes Benefits of Using a Connected, Reusable Auto-Injector for Self-Injecting Biologics: A Narrative Review. 2023. Full text: PMC10567963.
39. European Medicines Agency (EMA). Quality documentation for medicinal products when used with a medical device — Scientific guideline. EMA/CHMP/QWP/BWP/259165/2019. Effective 1 January 2022.
40. European Medicines Agency (EMA). Guideline on quality requirements for drug-device combinations. EMA/CHMP/QWP/BWP/259165/2019. Includes compatibility, performance testing, container-closure and device-component expectations.
41. ISO 11040-8:2026. Prefilled syringes — Part 8: Requirements and test methods for finished prefilled syringes. International Organization for Standardization.